

(51) International Patent Classification:
C07K 16/08 (2006.01)(21) International Application Number:
PCT/IB2019/000541(22) International Filing Date:
13 May 2019 (13.05.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18382327.7 14 May 2018 (14.05.2018) EP
18382359.0 25 May 2018 (25.05.2018) EP
19382208.7 26 March 2019 (26.03.2019) EP
19382331.7 03 May 2019 (03.05.2019) EP(71) Applicants: **MOSAIC BIOMEDICALS SLU** [ES/ES];
Barcelona Science Park, C/Baldiri Reixac, 4-8 Torre "I",
7a Planta, 08028 Barcelona (ES). **FUNDACIÓ PRIVA-
DA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA
DE VALL HEBRON** [ES/ES]; Natzaret, 115-117, Edifi-
ci Cellex, 08035 Barcelona (ES). **FUNDACIÓ PRIVADA
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS****AVANÇATS** [ES/ES]; Recerca I Estudis Avançats, Passeig
Lluís Companys, 23, 08010 Barcelona (ES).(72) Inventors: **SEOANE SUAREZ, Joan**; Carrer Natzaret,
115-117, Edifici Cellex, 08035 Barcelona (ES). **ANIDO
FOLGUEIRA, Judit**; Carrer Natzaret, 115-117, Edifici
Cellex, 08035 Barcelona (ES).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTIBODIES AGAINST LIF AND DOSAGE FORMS THEREOF




Fig. 27B

(57) Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer and effective doses of these antibodies.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*